pazopanib + abexinostat

A combination of **pazopanib**, a small molecule tyrosine kinase inhibitor of **VEGFR**, **PDGFR**, and **c-KIT**, with **abexinostat**, a small molecule **histone deacetylase (HDAC) inhibitor**. This regimen is being investigated for its capacity to enhance anti-tumor activity and reverse resistance to angiogenesis inhibitors in patients with advanced solid tumor malignancies, particularly *renal cell carcinoma (RCC)*. In clinical studies, this combination showed prolonged disease control and durable responses, even in patients previously refractory to VEGF inhibitors. **Pazopanib** inhibits the angiogenic signaling pathways, while **abexinostat** modulates gene expression via epigenetic regulation, downregulating hypoxia-inducible factor-1α (HIF-1α) and targeting HDAC2 to complement anti-angiogenic effects[1][2][5].

Other names

pazopanib + abexinostat